Questions discussed in this category
Do you generally recommend anti-diarrheals, dietary modifications, or consider this an unacceptable side effect and move to other therapies?
Are there specific guidelines for managing this patient population?
Since free light chains are removed by dialysis and SPEP can also be impacted, is there a reliable way to monitor patients with ESRD and MM?
No transfusion dependence but has hemoglobin in the 8-9 g/dl range.
If there are light chain deposits on the kidney, is that conclusive of MGRS?
Would you bridge with enoxaparin 0.7 mg/kg/day in an ESKD patient, as described in a previous retrospective study (Pon et al., PMID: 24718051)?
- Dialysis catheter used for hemodialysis- RIJ thrombus in dialysis catheter was incidentally found- Patient asymptomatic with no prior history of VTE...
Does transplant eligibility make a difference for management?
195232121320638207762053919820197981721918632185111291018153174071808917069169411682797941644716508158231483413902957413236102206518
Papers discussed in this category
PLoS One, 2021 Apr 08
Am J Kidney Dis, 2019 Aug 05
Circulation, 2022 Nov 06
Circulation, 2022 Nov 06
J Rheumatol, 2017 May 15
Circulation, 2011-12-20
American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013-01
American journal of nephrology, 2013
Journal of the American Heart Association, 2021 Jun 26
Therapeutic drug monitoring, 2022 Jun 01
American journal of kidney diseases : the official journal of the National Kidney Foundation, 2019 Jan 17
Nephrology (Carlton, Vic.), 2019 Oct 23
European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 2021 Dec 06